The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on May 23, 2025. This approval, identified as BLA 125554 S-133, was based on efficacy data submitted by the sponsor, Bristol Myers Squibb.
Background
Nivolumab, marketed under the brand name Opdivo, is a pharmaceutical product developed by Bristol Myers Squibb. This supplemental application specifically addresses the drug's efficacy, indicating a review of its effectiveness for a particular use or population.
What this means
This supplemental approval signifies that the FDA has reviewed and acknowledged additional efficacy data for nivolumab. While the specific details of the expanded indication or patient population are not explicitly stated in this public record, the approval under the 'efficacy' classification confirms the agency's positive assessment of the drug's effectiveness for the scope of this application. This development may lead to updates in the prescribing information for clinicians, potentially offering new or refined treatment options for patients.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The record for BLA 125554 S-133, pertaining to Opdivo (nivolumab) and categorized under efficacy, was posted on May 23, 2025, on accessdata.fda.gov.